Therapists & Referring Providers
Collaborative Care for Patients Receiving Treatment
Our goal is not to replace therapy, but to complement and strengthen it.
Who it is for
Licensed Mental Health Professionals
At Reyou, we view ketamine therapy and Spravato® as powerful clinical tools that work best when integrated into a broader continuum of care. We actively seek collaboration with therapists and providers who want to support their patients through these treatments — before, during, and after the experience.
This page is intended for licensed mental health professionals and medical providers such as:
Psychotherapists and psychologists
Psychiatrists and psychiatric nurse practitioners
Social workers and counselors
Group practices and
medical providers
If you are working with patients who may benefit from ketamine therapy or Spravato®, we welcome collaboration and conversation.
Adjunctive Treatments
Spravato® Therapy
Spravato® is FDA-approved for treatment-resistant depression and for depressive symptoms associated with suicidal thoughts and is often covered by insurance.
Ketamine Therapy
Ketamine therapy may be appropriate for a broader range of conditions, including depression, anxiety, PTSD, OCD, addiction, postpartum depression, and trauma-related symptoms.
At Reyou, both ketamine therapy and Spravato® play meaningful roles depending on a patient’s clinical needs and history.
While these treatments can create meaningful shifts, we believe their greatest value comes when paired with ongoing therapeutic work.
The Neuroplasticity Window
Both ketamine and Spravato® can temporarily increase neuroplasticity and reduce rigid patterns of thinking. Many patients report feeling more open and receptive in the hours and days following treatment.
We encourage patients to engage in psychotherapy within 24 to 48 hours after treatment, when insight and emotional flexibility may be most accessible.
Integration and continuity
Coordinated Integration Support
Integration is a core part of how we practice at Reyou. We support patients in reflecting on their experience and identifying what may be meaningful to carry forward.
With patient consent, we collaborate with referring therapists to support continuity while respecting therapeutic boundaries. This includes:
Shared care plans
Clear communication boundaries
Coordination during neuroplasticity
When Referral May Be Appropriate
Consider referral for patients who:
Have had limited response to traditional treatment approaches
Experience significant depressive symptoms or suicidal thoughts
Are engaged in therapy and seeking adjunctive support
We will provide thorough screening to ensure appropriate fit.
Our responsibilities
Clinical Oversight & Safety
All treatments are delivered under medical supervision with careful screening and monitoring. Our team includes medical doctors and psychiatric nurse practitioners experienced in ketamine, Spravato®, and medication interactions.
This includes:
Careful screening and eligibility review
Ongoing monitoring and support
Adherence to FDA and REMS requirements
Ongoing evaluation throughout the care
Safety is never compromised for experience — both are designed to work together.
We are actively interested in building collaborative relationships with therapists and providers. Fill out the inquiry form, and we’ll connect to discuss collaboration.